- Conditions
- Ultrasonography, Multiple Trauma, Kidney Calculi, Aortic Aneurysm, Abdominal, Pregnancy, Catheterization, Venous
- Interventions
- EFAST exam, Pelvic Ultrasound, Ultrasound Guided Vascular Access, Focused Ultrasound Scan, Cardiac Ultrasound
- Device · Procedure
- Lead sponsor
- Keller Fire Rescue
- Government
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Keller, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,176
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia, Adult
- Interventions
- ADI-PEG 20
- Drug
- Lead sponsor
- Polaris Group
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Miami, Florida • Charlotte, North Carolina • Houston, Texas
- Conditions
- Heart Diseases
- Interventions
- Education + Patient Navigation, Self-care Education
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 30 Years to 90 Years · Male only
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Bessemer, Alabama • Birmingham, Alabama
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- Healing Touch & Guided Imagery
- Other
- Lead sponsor
- Scripps Center for Integrative Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Congenital Heart Disease in Children
- Interventions
- No intervention. It is observational
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
- Conditions
- Congenital Heart Disease (CHD)
- Interventions
- Breastfeeding clinical practice guideline (CPG) for congenital heart disease (CHD)
- Other
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
- Conditions
- Cardiovascular Diseases
- Interventions
- Gardening and Nutrition Advice, Nutrition Advice
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 20 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
- Interventions
- Carvedilol
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 2 Diabetes Mellitus, Coronary Artery Disease
- Interventions
- Aspirin
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Embolic Stroke of Undetermined Source, Transient Ischemic Attack, Right-To-Left Atrial Shunt, Patent Foramen Ovale
- Interventions
- NeuralBot Investigational System, Transthoracic Echocardiography (TTE)
- Diagnostic Test
- Lead sponsor
- NeuraSignal Inc dba NovaSignal
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Portland, Oregon • Chattanooga, Tennessee + 3 more
- Conditions
- Heart Failure, Mild Cognitive Impairment
- Interventions
- Vita, Com, Vita+Com
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Cognitive Function, Preclinical, Chronic Kidney Diseases, Older Adults
- Interventions
- Partially supervised home-based walking exercise, Control
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fabry Disease
- Interventions
- Pegunigalsidase-alfa
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 3 more
- Conditions
- Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
- Interventions
- Placebo Administration, Questionnaire Administration, Telotristat Ethyl
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Determine COPD prevalence utilizing spirometry along with CT scans and symptom assessments in the THCI lung cancer screening populatio
- Diagnostic Test
- Lead sponsor
- Temple University
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Fabry Disease
- Interventions
- Iohexol
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 5 Years to 25 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- La Jolla, California • Decatur, Georgia • Cincinnati, Ohio + 2 more
- Conditions
- Heart Failure
- Interventions
- Provider Focus, Patient Interview, PROs/Clinical Data Integration
- Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,033 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Murray, Utah
- Conditions
- Pulmonary Hypertension
- Interventions
- No Intervention
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
- Interventions
- Biospecimen Collection, Cediranib Maleate, Computed Tomography, Computed Tomography with Contrast, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 384
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more
- Conditions
- Coronary Artery Disease
- Interventions
- Colchicine 0.5 MG
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Atrial Fibrillation, Stroke
- Interventions
- Chart Review
- Other
- Lead sponsor
- MaineHealth
- Other
- Eligibility
- Not listed
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rockport, Maine
- Conditions
- ISCHEMIC CARDIOMYOPATHY
- Interventions
- Manganese-enhanced MRI contrast reagent, Gadolinium-enhanced MRI contrast reagent
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Interventions
- BYDUREON, Placebo
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Elderly, Coronary Arterial Disease (CAD)
- Interventions
- In-Person Group Singing, instructional sing-along video series, Weekly health education
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin